Media Coverage

Quest Diagnostics and Scipher Medicine announced a collaboration designed to expand patient access to diagnostic services for rheumatoid arthritis. Under a multiyear collaboration, Quest will provide RNA extraction and next-generation sequencing services for Scipher’s PrismRA test, a blood-based molecular signature response classifier aimed at predicting a patient’s response to TNF inhibitor therapy.

Quest Diagnostics unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives.

On this episode I talked to Michael Racke, MD Medical Director of Neurology at Quest Diagnostics. Michael discusses promising advancements in our understanding and treatment of Alzheimer’s disease. He explains how imaging and biomarkers have allowed earlier and more accurate diagnosis, moving from just a clinical picture to actually visualizing amyloid plaques and tau tangles in the brain.

Quest Diagnostics said Thursday that its Haystack Oncology subsidiary has entered a collaboration agreement with Rutgers Cancer Institute of New Jersey for a study of early-stage triple-negative breast cancer patients. Researchers will use Haystack's MRD technology to help evaluate therapeutic response and collect molecular information on individuals undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin.

Secaucus-based Quest Diagnostics on Thursday said it was awarded a contract by the Centers for Disease Control and Prevention designed to assess the burden of hepatitis C virus in the U.S. The agreement marks a new phase of a decadelong collaboration between Quest and the CDC to improve hepatitis public health research based on insights from laboratory data.